Predict your next investment

Venture Capital
bluestonevp.com

See what CB Insights has to offer

Investments

6

Portfolio Exits

1

Funds

1

About Bluestone Venture Partners

BlueStone Venture Partners is a venture capital firm that teams with inspired entrepreneurs to develop their visions to build industry-leading companies in business to business market segments. BlueStone provides strategic capital and support to early-stage life science companies in the medical devices, health IT, advanced materials and molecular diagnostics fields. BlueStone is based in Tucson, Arizona and Santa Fe, New Mexico.

Bluestone Venture Partners Headquarter Location

Tucson, Arizona,

United States

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Latest Bluestone Venture Partners News

Elucid Raises $27M in Series B Funding

Jun 23, 2022

Elucid , a Boston, MA-company developing non-invasive medical software to characterize cardiovascular disease, raised $27M in Series B funding. The round was led by an undisclosed strategic investor, with participation from Biovision Ventures, and existing investors, including MedTex Ventures, IAG Capital, Bold Brain Ventures, and BlueStone Venture Partners. The company intends to use the funds to accelerate growth and its development efforts. Led by CEO Blake Richards, Elucid is a medical technology company using interpretable and validated AI to provide physicians with a software platform to optimize treatment decisions for patients with cardiovascular disease. The FDA-Cleared and CE-marked non-invasive software quantifies atherosclerotic plaque characteristics compared to histopathology, including Lipid Rich Necrotic Core. Specifically, the algorithms developed through machine learning characterize tissue types in the artery wall known to cause heart attacks, such as lipid rich necrotic core. The capability to discern complex plaque biology at the cellular and molecular level is powering new applications that can derive fractional flow reserve (FFRct), risk of heart attack/stroke, and expression prediction to inform therapeutic selection. This approach enables physicians to diagnose the direct cause of chest pain but also to determine if patients have early-stage heart disease which cannot be seen by alternative methods. The software is available for commercial use in the U.S., Europe, and South Korea. FinSMEs

Bluestone Venture Partners Investments

6 Investments

Bluestone Venture Partners has made 6 investments. Their latest investment was in Elucid as part of their Series B on June 6, 2022.

CBI Logo

Bluestone Venture Partners Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

6/23/2022

Series B

Elucid

$27M

No

2

10/12/2021

Series B

Subscribe to see more

$99M

Subscribe to see more

10

5/10/2021

Series A

Subscribe to see more

$99M

Subscribe to see more

10

5/15/2019

Series B - IV

Subscribe to see more

$99M

Subscribe to see more

10

11/26/2018

Series A

Subscribe to see more

$99M

Subscribe to see more

10

Date

6/23/2022

10/12/2021

5/10/2021

5/15/2019

11/26/2018

Round

Series B

Series B

Series A

Series B - IV

Series A

Company

Elucid

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Amount

$27M

$99M

$99M

$99M

$99M

New?

No

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

2

10

10

10

10

Bluestone Venture Partners Portfolio Exits

1 Portfolio Exit

Bluestone Venture Partners has 1 portfolio exit. Their latest portfolio exit was Paradigm Diagnostics on March 03, 2020.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

3/3/2020

Acquired

$99M

2

Date

3/3/2020

Exit

Acquired

Companies

Valuation

$99M

Acquirer

Sources

2

Bluestone Venture Partners Fund History

1 Fund History

Bluestone Venture Partners has 1 fund, including BlueStone Life Science Innovation & Technology Fund.

Closing Date

Fund

Fund Type

Status

Amount

Sources

12/23/2019

BlueStone Life Science Innovation & Technology Fund

Multi-Stage Venture Capital

Open

$8.9M

1

Closing Date

12/23/2019

Fund

BlueStone Life Science Innovation & Technology Fund

Fund Type

Multi-Stage Venture Capital

Status

Open

Amount

$8.9M

Sources

1

Bluestone Venture Partners Team

2 Team Members

Bluestone Venture Partners has 2 team members, including current Founder, Managing Director, Mara Aspinall.

Name

Work History

Title

Status

Mara Aspinall

Founder, Managing Director

Current

Thomas Nickoloff

Managing Director

Current

Name

Mara Aspinall

Thomas Nickoloff

Work History

Title

Founder, Managing Director

Managing Director

Status

Current

Current

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.